{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:28:18Z","timestamp":1793899698402,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CIHR #408004"],"award-info":[{"award-number":["CIHR #408004"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00415-026-14147-8","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:46:11Z","timestamp":1790243171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["What have trials targeting amyloid in Alzheimer\u2019s told us to date? The conversation the Alzheimer\u2019s field isn\u2019t having"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-3765","authenticated-orcid":false,"given":"Adrian M.","family":"Owen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"14147_CR1","doi-asserted-by":"publisher","unstructured":"Nonino F, Minozzi S, Sambati L, et al. Amyloid\u2010beta\u2010targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer\u2019s disease - Nonino, F - 2026 | Cochrane Library. Accessed May 5, 2026. https:\/\/www.cochranelibrary.com\/cdsr\/doi\/https:\/\/doi.org\/10.1002\/14651858.CD016297\/full","DOI":"10.1002\/14651858.CD016297\/full"},{"key":"14147_CR2","unstructured":"Commissioner O of the. FDA Converts Novel Alzheimer\u2019s Disease Treatment to Traditional Approval. FDA. September 12, 2025. Accessed May 5, 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"},{"key":"14147_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566\u2013572. https:\/\/doi.org\/10.1192\/bjp.140.6.566","journal-title":"Br J Psychiatry"},{"issue":"1","key":"14147_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"issue":"6","key":"14147_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"issue":"1","key":"14147_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70058","volume":"11","author":"LE Stoeckel","year":"2025","unstructured":"Stoeckel LE, Fazio EM, Hardy KK, Kidwiler N, McLinden KA, Williams B (2025) Clinically meaningful outcomes in Alzheimer\u2019s disease and Alzheimer\u2019s disease related dementias trials. Alzheimers Dement (N Y) 11(1):e70058. https:\/\/doi.org\/10.1002\/trc2.70058","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"14147_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1192\/bjp.bp.116.182048","volume":"210","author":"JD Huntley","year":"2017","unstructured":"Huntley JD, Hampshire A, Bor D, Owen A, Howard RJ (2017) Adaptive working memory strategy training in early Alzheimer\u2019s disease: randomised controlled trial. Br J Psychiatry 210(1):61\u201366. https:\/\/doi.org\/10.1192\/bjp.bp.116.182048","journal-title":"Br J Psychiatry"},{"issue":"5","key":"14147_CR8","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1002\/alz.13770","volume":"20","author":"RT Muir","year":"2024","unstructured":"Muir RT, Hill MD, Black SE, Smith EE (2024) Minimal clinically important difference in Alzheimer\u2019s disease: rapid review. Alzheimers Dement 20(5):3352\u20133363. https:\/\/doi.org\/10.1002\/alz.13770","journal-title":"Alzheimers Dement"},{"issue":"8","key":"14147_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027062","volume":"9","author":"H Zhang","year":"2019","unstructured":"Zhang H, Huntley J, Bhome R et al (2019) Effect of computerised cognitive training on cognitive outcomes in mild cognitive impairment: a systematic review and meta-analysis. BMJ Open 9(8):e027062. https:\/\/doi.org\/10.1136\/bmjopen-2018-027062","journal-title":"BMJ Open"},{"issue":"1","key":"14147_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-023-00987-5","volume":"7","author":"ATC Chan","year":"2024","unstructured":"Chan ATC, Ip RTF, Tran JYS, Chan JYC, Tsoi KKF (2024) Computerized cognitive training for memory functions in mild cognitive impairment or dementia: a systematic review and meta-analysis. NPJ Digit Med 7(1):1. https:\/\/doi.org\/10.1038\/s41746-023-00987-5","journal-title":"NPJ Digit Med"},{"issue":"6","key":"14147_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003260.pub2","volume":"2013","author":"A Bahar-Fuchs","year":"2013","unstructured":"Bahar-Fuchs A, Clare L, Woods B (2013) Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer\u2019s disease and vascular dementia. Cochrane Database Syst Rev 2013(6):CD003260. https:\/\/doi.org\/10.1002\/14651858.CD003260.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"14147_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102312","volume":"97","author":"R Desai","year":"2024","unstructured":"Desai R, Leung WG, Fearn C, John A, Stott J, Spector A (2024) Effectiveness of cognitive stimulation therapy (CST) for mild to moderate dementia: a systematic literature review and meta-analysis of randomised control trials using the original CST protocol. Ageing Res Rev 97:102312. https:\/\/doi.org\/10.1016\/j.arr.2024.102312","journal-title":"Ageing Res Rev"},{"key":"14147_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1192\/bjp.183.3.248","volume":"183","author":"A Spector","year":"2003","unstructured":"Spector A, Thorgrimsen L, Woods B et al (2003) Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry 183:248\u2013254. https:\/\/doi.org\/10.1192\/bjp.183.3.248","journal-title":"Br J Psychiatry"},{"issue":"5","key":"14147_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/pgfar05050","volume":"5","author":"M Orrell","year":"2017","unstructured":"Orrell M, Hoe J, Charlesworth G et al (2017) Support at home: interventions to enhance life in dementia (SHIELD) evidence, development and evaluation of complex interventions. Programme Grants Appl Res 5(5):1\u2013184. https:\/\/doi.org\/10.3310\/pgfar05050","journal-title":"Programme Grants Appl Res"},{"issue":"6","key":"14147_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001190.pub3","volume":"6","author":"JS Birks","year":"2018","unstructured":"Birks JS, Harvey RJ (2018) Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev 6(6):CD001190. https:\/\/doi.org\/10.1002\/14651858.CD001190.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"14147_CR16","unstructured":"Aducanumab to Be Discontinued as Alzheimer\u2019s Treatment | alz.org. Alzheimer\u2019s Association. Accessed May 5, 2026. https:\/\/www.alz.org\/alzheimers-dementia\/treatments\/aducanumab"},{"key":"14147_CR17","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-215699","author":"CK Kim","year":"2022","unstructured":"Kim CK, Lee YR, Ong L, Gold M, Kalali A, Sarkar J (2022) Alzheimer\u2019s disease: key insights from two decades of clinical trial failures. J Alzheimers Dis. https:\/\/doi.org\/10.3233\/JAD-215699","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"14147_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70098","volume":"11","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Zhou Y, Lee G et al (2025) Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimer\u2019s Dementia Trans Res Clin Intervent 11(2):e70098. https:\/\/doi.org\/10.1002\/trc2.70098","journal-title":"Alzheimer\u2019s Dementia Trans Res Clin Intervent"},{"issue":"3","key":"14147_CR19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3233\/JAD-201606","volume":"81","author":"YY Wang","year":"2021","unstructured":"Wang YY, Ge YJ, Tan CC, Cao XP, Tan L, Xu W (2021) The proportion of APOE4 carriers among non-demented individuals: a pooled analysis of 389,000 community-dwellers. J Alzheimers Dis 81(3):1331\u20131339. https:\/\/doi.org\/10.3233\/JAD-201606","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"14147_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"RJ Bateman","year":"2011","unstructured":"Bateman RJ, Aisen PS, De Strooper B et al (2011) Autosomal-dominant Alzheimer\u2019s disease: a review and proposal for the prevention of Alzheimer\u2019s disease. Alzheimers Res Ther 3(1):1. https:\/\/doi.org\/10.1186\/alzrt59","journal-title":"Alzheimers Res Ther"},{"key":"14147_CR21","unstructured":"Alzheimer\u2019s Society and leading experts respond to claims anti-amyloid drugs are ineffective | Alzheimer\u2019s Society. Accessed May 5, 2026. https:\/\/www.alzheimers.org.uk\/blog\/alzheimers-society-and-leading-experts-respond-claims-anti-amyloid-drugs-are-ineffective?page"},{"issue":"8","key":"14147_CR22","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dementia 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"7","key":"14147_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34(7):939\u2013944. https:\/\/doi.org\/10.1212\/wnl.34.7.939","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14147-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14147-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14147-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:05:43Z","timestamp":1793898343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14147-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["14147"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14147-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"1 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.O. is co-founder and Chief Scientific Officer of Creyos Inc., a company that develops and commercialises cognitive assessment tools. No other competing interests are declared.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"617"}}